Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC

BACKGROUND: Pembrolizumab (Pembro) in combination with chemotherapy has been approved for the treatment of pretreated advanced NSCLC in the United States and China for its significant efficacy. However, the cost‐effectiveness is unknown considering Pembro's high price. The impact of programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Ning, Zhang, Tian‐tian, Hua, Si‐hua, Lu, Zi‐luo, Ji, Bo, Li, Li‐xia, Lu, Li‐qing, Huang, Wen‐jie, Jiang, Jie, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050096/
https://www.ncbi.nlm.nih.gov/pubmed/31945265
http://dx.doi.org/10.1002/cam4.2793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050096/
https://www.ncbi.nlm.nih.gov/pubmed/31945265
http://dx.doi.org/10.1002/cam4.2793

Ejemplares similares